Medigene AG (MDGEF) Stock Analysis
DELISTED
What happened to Medigene AG (MDGEF) stock?
Medigene AG (MDGEF) no longer trades on public markets. The figures below are historical and are not a current quote.
- Status:
- Delisted — no longer trades
Market cap $38.2M is the value of all shares combined.
For informational purposes only. Not financial advice. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Medigene AG (MDGEF). Medigene AG is a German biotechnology company focused on developing T-cell immunotherapies for cancer, including T-cell receptor (TCR)-modified T cells.
Last analyzed: Jun 15, 2026Dated analysis: the newest financial statements on file are 28 months old (Jun 1, 2024), so the figures and score below describe that period, not today.
Medigene AG (MDGEF) Healthcare & Pipeline Overview
MDGEF OTC Market Information
MDGEF trades on the OTC Other market tier of OTC Markets.
- OTC Tier: OTC Other
More about this archive record
Can I still buy MDGEF shares?
No. MDGEF stopped trading on public markets, so the shares are not available through a broker. Anything you see quoted for MDGEF elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before MDGEF stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Medigene AG. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.